{"id":654191,"date":"2023-06-05T07:04:01","date_gmt":"2023-06-05T07:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=654191"},"modified":"2023-06-05T07:04:01","modified_gmt":"2023-06-05T07:04:01","slug":"frontotemporal-dementia-market-to-exhibit-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-neurimmune-alector-autifony-oncolys-passage-bio-camp4","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/frontotemporal-dementia-market-to-exhibit-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-neurimmune-alector-autifony-oncolys-passage-bio-camp4_654191.html","title":{"rendered":"Frontotemporal Dementia Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Neurimmune, Alector, Autifony, Oncolys, Passage Bio, CAMP4"},"content":{"rendered":"
\n
\"Frontotemporal<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Frontotemporal Dementia market size in seven major markets was USD 92 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 16% for the study period (2019\u20132032). The Frontotemporal Dementia Market is anticipated to evolve immensely in the coming years owing to the expected approval of emerging therapy and the increasing patient population of Frontotemporal Dementia in the 7MM.<\/div>\n

DelveInsight’s “Frontotemporal Dementia Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Frontotemporal Dementia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Frontotemporal Dementia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Frontotemporal Dementia treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Frontotemporal Dementia: An Overview<\/strong><\/p>\n

FTD is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behavior, and language. There are three types of frontotemporal disorders (FTD): behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and movement disorders.<\/p>\n

FTD is considered young-onset dementia, occurring mainly between the ages of 45 to 65, and is the most common dementia in those under 60 years of age. FTD occurs when brain cells in the frontal or temporal lobes die due to the build-up of abnormal proteins, leading to abnormal brain function, and more cell deaths result in brain atrophy. FTD encompasses clinical disorders that include changes in behavior, language, executive control, and often motor symptoms.<\/p>\n

Frontotemporal Dementia Market Key Facts<\/strong><\/p>\n